Physiological Complexity of Gait Over the First Six Months Post Stroke

Status Completed

Clinical Trial Summary

Physiological complexity of gait, a measure of the interaction of multiple control mechanisms for walking within a biological system, is decreased in persons with chronic stroke compared to those without disability. Thus, it is assumed that the quantification of gait complexity represents the adaptability and health of the individual. However, it is unknown if the level of gait-related complexity improves over time with recovery from stroke. Therefore, the primary purpose of this study is to determine if the physiological complexity of gait changes over the first six months post stroke within the contemporary healthcare environment. Secondary aims include 1) determining if there is a difference between the amount of physiological complexity of gait and lateralization of hemispheric damage after stroke and 2) exploring the relationship of complexity to lower extremity motor impairment, walking speed and balance. Sixty individuals within one month post stroke from the greater Indianapolis area will be recruited for this prospective, longitudinal outcomes study. Testing sessions will occur at intervals across the first six months post stroke: within 1 month, at 3 months, and at 6 months post stroke. During each testing session, participants will complete a 2-minute walking task during which accelerometer signals from wireless inertial measurement units will be collected and converted to sample entropy to quantify the physiological complexity of gait. Additionally, measures to quantify lower extremity motor impairment, walking speed and balance will be collected and analyzed. Changes in complexity of gait from early to later stages of stroke recovery may serve as a foundation for prognosticating outcomes, such as predicting capacity for community mobility and/or risk of fall. The proposed study will meet a critical need to develop methods that differentiate among capacities for adapting movement patterns in individuals with neurological dysfunction. This work will ultimately build upon evidence that will assist therapists in tailoring interventions in such a way to optimize function.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02541578
Study type	Observational
Source	University of Indianapolis
Contact
Status	Completed
Phase
Start date	August 11, 2015
Completion date	September 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05378035` - DOAC in Chinese Patients With Atrial Fibrillation
Completed	`NCT03574038` - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke	N/A
Completed	`NCT03679637` - Tablet-based Aphasia Therapy in the Acute Phase After Stroke	N/A
Completed	`NCT03633422` - Evaluation of Stroke Patient Screening
Completed	`NCT04088578` - VNS-supplemented Motor Retraining After Stroke	N/A
Not yet recruiting	`NCT05534360` - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Withdrawn	`NCT05786170` - ERILs Und SNILs Unter SOC	N/A
Not yet recruiting	`NCT04105322` - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients	N/A
Recruiting	`NCT03132558` - Contrast Induced Acute Kidney in Patients With Acute Stroke	N/A
Completed	`NCT02893631` - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting	`NCT02274727` - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed	`NCT02225730` - Imaging Collaterals in Acute Stroke (iCAS)
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Active, not recruiting	`NCT01581502` - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Completed	`NCT00761982` - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.	Phase 1/Phase 2
Completed	`NCT00535197` - Autologous Bone Marrow Stem Cells in Ischemic Stroke.	Phase 1/Phase 2
Terminated	`NCT00132509` - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke	Phase 2
Recruiting	`NCT05760326` - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.